All Studies

These pages contain general information on studies associated with the Center.

Study 01 – Genetics of Opioid DependenceJoel GelernterOpioid-Cocaine DependenceAvailable at NIDA
Study 02 – Mapping Susceptibility Genes for Nicotine DependenceMing D. LiNicotine DependenceAvailable at NIDA
Study 03 – Molecular Genetics of Heroin Dependence in ChinaMing TsuangOpioid DependenceAvailable at NIDA and dbGaP
Study 05 – Addictions, Genotypes, Polymorphisms, and FunctionMaryJeanne KreekOpioid DependenceAvailable at NIDA and dbGaP
Study 06 – The Genetics of Vulnerability to NicotinePamela MaddenNicotine DependenceAvailable at NIDA and dbGaP
Study 07 – An Introduction to the Family Study of CocaineLaura BierutCocaine DependenceAvailable at NIDA
Study 08 – Mu Opioid Receptor Gene in Heroin AddictsLei YuOpioid DependenceAvailable at NIDA
Study 09 – Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics ConsortiumOvide PomerleauNicotine DependenceAvailable at NIDA
Study 10 – Pharmacokinetics of Nicotine in TwinsGary SwanNicotine DependenceAvailable at NIDA
Study 11 – Adolescent Drug DependenceJohn HewittPolysubstance DependenceAvailable at NIDA and dbGaP
Study 12 – Substance Abuse and the Dopamine System GenesMichael M. YanyukovPolysubstance DependenceAvailable at NIDA
Study 13 – Genetics of Cocaine Induced PsychosisJoseph F. CubellsCocaine DependenceAvailable at NIDA
Study 14 – Genome-Wide Analysis for Addiction Susceptibility GenesHerb LachmanOpioid DependenceAvailable at NIDA and dbGaP
Study 15 – Nicotine DependenceLaura BierutNicotine DependenceAvailable at NIDA
Study 16 – Nicotine DependenceMark LeppertNicotine DependenceAvailable at NIDA
Study 17 – Opioid DependenceWade BerrettiniOpioid DependenceAvailable at NIDA and dbGaP
Study 18 – Opioid Dependence: Candidate Genes and G x E EffectsElliot NelsonOpioid DependenceAvailable at NIDA
Study 19 – Epidemiological Study of Substance AbuseRob PhilibertPolysubstance DependenceAvailable at NIDA
Study 20 – Innovative Approaches for Cocaine PharmacotherapyHenry KranzlerOpioid-Cocaine DependenceAvailable at NIDA
Study 21 – Twin Family Study of Vulnerability to Substance AbuseWilliam IaconoPolysubstance DependenceCombined with Study 25
Study 22 – Exploring the Genetic Basis for Drug UseHallam HurtPolysubstance DependenceClosed
Study 23 – Substance Use Disorder Liability: Candidate Gene SystemMichael M. VanyukovPolysubstance DependenceAvailable at NIDA
Study 24 – START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START)Wade BerrettiniOpioid DependenceAvailable at NIDA and dbGaP
Study 25 – The Genes, Environment, and Development Initiative (GEDI)William IaconoOtherAvailable at dbGaP
Study 26 – The Genes, Environment, and Development Initiative (GEDI)E. Jane CostelloOtherAvailable at dbGaP
Study 27 – The Genetic Study of Nicotine Dependence in African Americans (AAND)Laura BierutNicotine DependenceAvailable at NIDA
Study 28 – Center on Antisocial Drug Dependence: the Genetics of HIV Risk BehaviorJohn HewittOtherTBA
Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048David A. NielsenCocaine DependenceTBA
Study 30 – Phase 2: Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Nepicastat for Cocaine DependenceThomas R. KostenCocaine DependenceTBA
Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051John RotrosenSmokescreenAvailable at dbGaP
Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053Kevin GrayOtherTBA
Study 33 – Genome-wide Association Study of HIV-1 Host Genetics Among Injection Drug UsersEric JohnsonOtherAvailable at dbGaP
Study 34 – Attention Deficit-Hyperactivity Disorder (ADHD)Robert K. MoyzisOtherTBA
Study 35 – Genetically Informative Smoking Cessation TrialLi-Shiun ChenNicotine DependenceAvailable at NIDA
Study 36 – Genetic Dissection in Pedigrees of Substance Use and Mood Disorders ComorbidityNelson B. FreimerOtherTBA
Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use DisorderMadhukar TrivediOtherTBA (370 samples will be collected over the next 2 years)
Study 38 – Adolescent Brain Cognitive Development (ABCD) StudyOtherAvailable at NDA
Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT)Adam BisagaOpioid DependenceTBA
Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY)Gavin BartOpioid DependenceTBA
Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder PharmacotherapyEdward NunesOpioid DependenceTBA
Study 42 – Genetics Analysis of Substance Use Disorder Using the Indiana Biobank DataDongbing LaiOtherTBA
Study 43 – Pediatric Imaging, Neurocognition, and Genetics (PING)Terry JerniganOtherTBA
Study 44 – Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2); CTN-0109Madhukar TrivediCocaine DependenceTBA
Study 45 – Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB); CTN-0110Steve ShoptawPolysubstance DependenceTBA
Study 46 – Advancing Genomics Research of Substance Use Disorders in Latin American PopulationsJanitza Montalvo-Ortiz & Humberto NicoliniPolysubstance DependenceTBA
Study 51 – Genotyping on Smokescreen Microarray ChipJasmin Vassileva & Alexandre TodorovSmokescreenAvailable at dbGaP; dbGaP
Study 52 – Genetic Contribution to the Abuse Liability of OxycodoneJermaine JonesSmokescreenAvailable at dbGaP
Study 53 – The Women’s Interagency HIV Study (WIHS)Brad AouizeratSmokescreenAvailable at dbGaP
Study 54 – Genotyping on Smokescreen Microarray ChipDeborah MashSmokescreenAvailable at dbGaP
Study 55 – ALIVE Cohort Smokescreen GWASBrion MaherSmokescreenAvailable at dbGaP
Study 56 – Assess the Cardiovascular, Cognitive, and Subjective Effects of Atomoxetine in Combination with IV MethamphetamineEdythe LondonSmokescreenAvailable at dbGaP
Study 57 – Neural Systems, Inhibitory Control, and Methamphetamine DependenceEdythe LondonSmokescreenAvailable at dbGaP
Study 58 – Early Methamphetamine Abstinence fMRI and Brain FunctionEdythe LondonSmokescreenAvailable at dbGaP
Study 59 – Smokescreen; Opioid/Cocaine Use; Antisocial Drug DependenceRobin CorleySmokescreenAvailable at dbGaP
Study 60 – Gene-Environment Interactions in COCCaINE Use Disorder: Collaborative Case-Control Initiative in Cocaine AddictionRodrigo Grassi-OliveiraSmokescreenAvailable at dbGaP
Study 61 – Smokescreen; NJD/NID CohortStanley WeissSmokescreenAvailable at dbGaP
Study 62 – Prevention of Viral Hepatitis and HIV in Drug Users – A Hepatitis B Model for HIV and an HB Vaccine Model (DASH)Lu-Yu HwangSmokescreenAvailable at dbGaP
Study 63 – Smokescreen; InC3 Cohort Substance AbusersKimberly PageSmokescreenAvailable at dbGaP
Study 64 – Smokescreen; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)Inga PeterSmokescreenAvailable at dbGaP
Study 65 – Spit for ScienceDanielle DickSmokescreenAvailable at dbGaP